Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

CISATRACURIUM BESYLATE injection Spojené státy - angličtina - NLM (National Library of Medicine)

cisatracurium besylate injection

zydus lifesciences limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . risk summary there are no adequate and well-controlled studies of cisatracurium besylate in pregnant women. animal studies conducted in rats administered cisatracurium besylate during organogen

Cisatracurium Accordpharma 2 mg/ml inj./inf. sol. i.v. vial Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium accordpharma 2 mg/ml inj./inf. sol. i.v. vial

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Accordpharma 2 mg/ml inj./inf. sol. i.v. vial Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium accordpharma 2 mg/ml inj./inf. sol. i.v. vial

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Accordpharma 2 mg/ml inj./inf. sol. i.v. vial Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium accordpharma 2 mg/ml inj./inf. sol. i.v. vial

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

CISATRACURIUM BESYLATE injection Spojené státy - angličtina - NLM (National Library of Medicine)

cisatracurium besylate injection

avet pharmaceuticals inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection, usp is indicated:        •as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age        •to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu        •to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection, usp is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection, usp is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection, usp have been reported [see warnings and precautions (5.4 )] . the use of 10 ml cisatracurium besylate injection, usp multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth w

CISATRACURIUM BESYLATE injection, solution Spojené státy - angličtina - NLM (National Library of Medicine)

cisatracurium besylate injection, solution

sagent pharmaceuticals - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . the use of 10 ml cisatracurium besylate multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warning